The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2025

Filed:

Feb. 15, 2024
Applicant:

Aptevo Research and Development Llc, Seattle, WA (US);

Inventors:

Gabriela Hernandez-Hoyos, Seattle, WA (US);

Elaine T. Sewell, Seattle, WA (US);

Catherine J. Mcmahan, Seattle, WA (US);

David Bienvenue, Seattle, WA (US);

John W. Blankenship, Seattle, WA (US);

Danielle Mitchell, Seattle, WA (US);

Peter Pavlik, Seattle, WA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 16/30 (2006.01); C12N 15/62 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 16/2866 (2013.01); C07K 16/2896 (2013.01); C07K 16/3061 (2013.01); C12N 15/62 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 16/005 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/75 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.


Find Patent Forward Citations

Loading…